CY1107973T1 - Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων - Google Patents
Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρωνInfo
- Publication number
- CY1107973T1 CY1107973T1 CY20081100554T CY081100554T CY1107973T1 CY 1107973 T1 CY1107973 T1 CY 1107973T1 CY 20081100554 T CY20081100554 T CY 20081100554T CY 081100554 T CY081100554 T CY 081100554T CY 1107973 T1 CY1107973 T1 CY 1107973T1
- Authority
- CY
- Cyprus
- Prior art keywords
- volume
- tumour
- present
- molecules
- relates
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 4
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 2
- 230000000890 antigenic effect Effects 0.000 title 1
- 210000000265 leukocyte Anatomy 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 230000000259 anti-tumor effect Effects 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 230000001024 immunotherapeutic effect Effects 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 210000002443 helper t lymphocyte Anatomy 0.000 abstract 1
- 238000009169 immunotherapy Methods 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Developmental Biology & Embryology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Η παρούσα εφεύρεση σχετίζεται με ανοσοθεραπευτικές μεθόδους, και μόρια και κύτταρα για χρήση σε ανοσοθεραπευτικές μεθόδους. Συγκεκριμένα, η παρούσα εφεύρεση σχετίζεται με την ανοσοθεραπεία του καρκίνου. Η παρούσα εφεύρεση σχετίζεται επιπλέον με πεπτιδικούς επιτόπους Τ-βοηθητικών κυττάρων που σχετίζονται με όγκους, μόνους ή σε συνδυασμό με άλλα πεπτίδια που σχετίζονται με όγκους, που λειτουργούν ως φαρμακευτικά συστατικά συνθέσεων εμβολίων τα οποία διεγείρουν αντικαρκινικές ανοσολογικές απαντήσεις. Συγκεκριμένα, η παρούσα εφεύρεση σχετίζεται με 49 νέες πεπτιδικές αλληλουχίες που προέρχονται από HLA μόρια τάξης II ανθρώπινων καρκινικών κυτταρικών σειρών που μπορούν να χρησιμοποιηθούν σε συνθέσεις εμβολίων για να επιφέρουν αντικαρκινικές ανοσολογικές απαντήσεις.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP05019254A EP1760088B1 (en) | 2005-09-05 | 2005-09-05 | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1107973T1 true CY1107973T1 (el) | 2013-09-04 |
Family
ID=35170099
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081100554T CY1107973T1 (el) | 2005-09-05 | 2008-05-28 | Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων |
| CY20101100169T CY1109849T1 (el) | 2005-09-05 | 2010-02-19 | Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι |
| CY20101100469T CY1110051T1 (el) | 2005-09-05 | 2010-05-27 | Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ii |
| CY20101100520T CY1110187T1 (el) | 2005-09-05 | 2010-06-11 | Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι |
| CY20111101223T CY1112186T1 (el) | 2005-09-05 | 2011-12-09 | Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20101100169T CY1109849T1 (el) | 2005-09-05 | 2010-02-19 | Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι |
| CY20101100469T CY1110051T1 (el) | 2005-09-05 | 2010-05-27 | Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ii |
| CY20101100520T CY1110187T1 (el) | 2005-09-05 | 2010-06-11 | Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι |
| CY20111101223T CY1112186T1 (el) | 2005-09-05 | 2011-12-09 | Πεπτιδια που σχετιζονται με ογκους τα οποια συνδεονται αδιακριτα σε μορια του αντιγονου ανθρωπινων λευκοκυτταρων (hla) ταξης ιι |
Country Status (23)
| Country | Link |
|---|---|
| US (6) | US10196432B2 (el) |
| EP (6) | EP1760088B1 (el) |
| JP (1) | JP5627180B2 (el) |
| KR (3) | KR101386790B1 (el) |
| CN (3) | CN105440119A (el) |
| AT (5) | ATE461214T1 (el) |
| AU (2) | AU2006289290B2 (el) |
| BR (1) | BRPI0615462A2 (el) |
| CA (2) | CA2929252A1 (el) |
| CY (5) | CY1107973T1 (el) |
| DE (4) | DE602005020047D1 (el) |
| DK (5) | DK1806359T3 (el) |
| EA (1) | EA013876B1 (el) |
| ES (5) | ES2341802T3 (el) |
| HK (1) | HK1220709A1 (el) |
| HR (2) | HRP20100128T1 (el) |
| NO (1) | NO340870B1 (el) |
| NZ (2) | NZ588813A (el) |
| PL (5) | PL1806359T3 (el) |
| PT (5) | PT1806359E (el) |
| SI (5) | SI1760088T1 (el) |
| UA (1) | UA98295C2 (el) |
| WO (1) | WO2007028574A2 (el) |
Families Citing this family (94)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2341802T3 (es) * | 2005-09-05 | 2010-06-28 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. |
| US20090004213A1 (en) * | 2007-03-26 | 2009-01-01 | Immatics Biotechnologies Gmbh | Combination therapy using active immunotherapy |
| UA103882C2 (uk) | 2007-07-27 | 2013-12-10 | Імматікс Біотекнолоджіс Гмбх | Композиція пухлино-асоційованих пептидів та відповідна протиракова вакцина |
| PL2562184T3 (pl) * | 2007-07-27 | 2016-03-31 | Immatics Biotechnologies Gmbh | Nowe immunogenne epitopy do immunoterapii |
| SI2183361T1 (sl) | 2007-07-27 | 2015-09-30 | Immatics Biotechnologies Gmbh | Nova imunoterapija proti nevronalnim in možganskim tumorjem |
| UA100127C2 (ru) | 2007-08-20 | 2012-11-26 | Онкотерапи Саенс, Инк. | Пептид cdh3 и лекарственное средство, содержащее его |
| US20100310640A1 (en) * | 2007-11-01 | 2010-12-09 | Knutson Keith L | Hla-dr binding peptides and their uses |
| PL2105501T3 (pl) | 2008-03-27 | 2016-03-31 | Immatics Biotechnologies Gmbh | Innowacyjna immunoterapia przeciwko nowotworom neuronów i mózgu |
| EP2113253B1 (en) * | 2008-04-30 | 2010-03-31 | Immatics Biotechnologies GmbH | Novel formulations of tumour-associated peptides binding to human leukocyte antigen (HLA) class I or II molecules for vaccines |
| NO2119726T3 (el) | 2008-05-14 | 2015-05-23 | ||
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| DK2172211T3 (en) * | 2008-10-01 | 2015-02-16 | Immatics Biotechnologies Gmbh | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
| HUE025796T2 (hu) * | 2009-01-28 | 2016-05-30 | Ind Tech Res Inst | Diabéteszes nefropátiához kapcsolt vizelet és szérum biomarkerek |
| WO2011073215A2 (en) | 2009-12-14 | 2011-06-23 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| GB201004551D0 (en) * | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
| GB201004575D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers |
| GB201009222D0 (en) | 2010-06-02 | 2010-07-21 | Immatics Biotechnologies Gmbh | Improved cancer therapy based on tumour associated antigens derived from cyclin D1 |
| NZ609916A (en) | 2010-12-14 | 2015-03-27 | Immatics Biotechnologies Gmbh | Hla-binding peptides derived from prostate-associated antigenic molecules and methods of use thereof |
| NZ743310A (en) * | 2011-03-23 | 2022-11-25 | Fred Hutchinson Cancer Center | Method and compositions for cellular immunotherapy |
| TWI775117B (zh) | 2013-08-05 | 2022-08-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二） |
| HRP20192262T1 (hr) | 2013-08-05 | 2020-03-06 | Immatics Biotechnologies Gmbh | Nova imunoterapija protiv nekoliko tumora, kao što su rak pluća, uključujući mikrocelularni karcinom pluća (nsclc) |
| GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
| HRP20191671T1 (hr) | 2014-05-09 | 2019-12-13 | Immatics Biotechnologies Gmbh | Nova imunoterapija za liječenje nekoliko tumora krvi, kao što je akutna mijeloidna leukemija (aml) |
| GB201408255D0 (en) * | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
| GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| SG10202102698VA (en) | 2014-12-23 | 2021-04-29 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers |
| ES2983924T3 (es) | 2015-03-27 | 2024-10-28 | Immatics Biotechnologies Gmbh | Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores |
| GB201505305D0 (en) * | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
| GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
| GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
| JP2018518956A (ja) * | 2015-06-19 | 2018-07-19 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 免疫療法で使用するための新規ペプチドおよびペプチド組み合わせおよび膵臓がんおよびその他のがんに対して使用するためにスキャフォールドを作製する方法 |
| IL308735A (en) | 2015-07-01 | 2024-01-01 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| RS61203B1 (sr) | 2015-07-06 | 2021-01-29 | Immatics Biotechnologies Gmbh | Novi peptidi i kombinacija peptida za upotrebu u imunoterapiji protiv raka jednjaka i drugih malignih tumora |
| GB201512369D0 (en) | 2015-07-15 | 2015-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against epithelial ovarian cancer and other cancers |
| GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
| PH12018501893A1 (en) | 2015-08-28 | 2022-05-02 | Immatics Biotechnologies Gmbh | Novel peptides, combination of peptides and scaffolds for use in immunotherapeutic treatment of various cancers |
| HK1258386A1 (zh) | 2015-10-05 | 2019-11-08 | Immatics Biotechnologies Gmbh | 用於小细胞肺癌和其他癌症免疫治疗的肽和肽组合物 |
| PE20230343A1 (es) | 2015-12-11 | 2023-03-01 | Immatics Biotechnologies Gmbh | Peptidos que estimulan respuestas inmunitarias antitumorales |
| US20170199961A1 (en) | 2015-12-16 | 2017-07-13 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
| GB201522667D0 (en) * | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
| GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
| IL302705A (en) | 2016-03-01 | 2023-07-01 | Immatics Biotechnologies Gmbh | Peptides, combination of peptides, and cell-based medicaments for use in immunotherapy against urinary bladder cancer and other cancers |
| GB201603568D0 (en) * | 2016-03-01 | 2016-04-13 | Immatics Biotechnologies Gmbh | Efficient treatment options including peptides and combination of peptide and cell based medicaments for use in immunotherapy against urinary bladder cancer |
| GB201603987D0 (en) | 2016-03-08 | 2016-04-20 | Immatics Biotechnologies Gmbh | Uterine cancer treatments |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| CA3018748A1 (en) * | 2016-03-31 | 2017-10-05 | Neon Therapeutics, Inc. | Neoantigens and methods of their use |
| AU2017247607B2 (en) | 2016-04-06 | 2021-08-19 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against AML and other cancers |
| CR20200608A (es) | 2016-04-21 | 2021-01-20 | Immatics Biotechnologies Gmbh | INMUNOTERAPIA CONTRA EL MELANOMA Y OTROS TIPOS DE CÁNCER (Divisional 2018-0551) |
| EA201892333A1 (ru) * | 2016-04-21 | 2019-03-29 | Имматикс Байотекнолоджиз Гмбх | Иммунотерапия меланомы и других видов рака |
| JP7075125B2 (ja) | 2016-05-25 | 2022-05-25 | イマティクス バイオテクノロジーズ ゲーエムベーハー | 標的としてのおよび胆嚢がんおよび胆管がんおよびその他のがんに対する免疫療法で使用するための新規ペプチド、ペプチド組み合わせ |
| RU2630647C1 (ru) * | 2016-05-27 | 2017-09-11 | Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства | ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К КОНФОРМАЦИОННОМУ ЭПИТОПУ С3 КОМПОНЕНТА КОМПЛЕМЕНТА ЧЕЛОВЕКА, ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), ЭКСПРЕССИОННЫЙ ВЕКТОР, СОДЕРЖАЩИЙ ПОСЛЕДОВАТЕЛЬНОСТЬ ДНК (ВАРИАНТЫ), И ШТАММ КЛЕТОК ЯИЧНИКОВ КИТАЙСКОГО ХОМЯЧКА CHO-humC34-ПРОДУЦЕНТ ДАННОГО ГУМАНИЗИРОВАННОГО АНТИТЕЛА |
| EP3469361B1 (en) | 2016-06-10 | 2024-07-31 | Gadeta B.V. | Novel method for identifying deltat-cell (or gammat-cell) receptor chains or parts thereof that mediate an anti-tumour or an anti-infective response |
| TWI796299B (zh) * | 2016-08-26 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 |
| KR102379955B1 (ko) | 2016-12-08 | 2022-03-29 | 이매틱스 바이오테크놀로지스 게엠베하 | 짝짓기가 향상된 t 세포 수용체 |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| TWI796314B (zh) | 2017-01-27 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於卵巢癌和其他癌症免疫治療的新型肽和肽組合物 |
| CR20210128A (es) | 2017-01-27 | 2021-04-26 | Immatics Biotechnologies Gmbh | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de ovario y otros tipos de cancer (divisional exp. 2019-388) |
| US10738100B2 (en) | 2017-01-27 | 2020-08-11 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
| EP3576767A4 (en) * | 2017-02-06 | 2020-12-02 | Academia Sinica | RECOMBINATED PROTEINS AND THEIR USES |
| WO2018189152A2 (en) | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
| TW201841934A (zh) | 2017-04-10 | 2018-12-01 | 德商英麥提克生物技術股份有限公司 | 用於治療癌症免疫治療的新穎肽及其肽組合物 |
| KR20190137858A (ko) | 2017-04-10 | 2019-12-11 | 이매틱스 바이오테크놀로지스 게엠베하 | 백혈병 및 다른 암에 대한 면역요법에 사용하기 위한 펩티드 및 펩티드의 조합 |
| EP3725327A3 (en) * | 2017-04-10 | 2021-01-20 | Immatics Biotechnologies GmbH | Peptides and combination thereof for use in the immunotherapy against cancers |
| WO2019007974A1 (en) | 2017-07-07 | 2019-01-10 | Immatics Biotechnologies Gmbh | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS |
| CR20210169A (es) | 2017-07-07 | 2021-06-10 | Immatics Biotechnologies Gmbh | NUEVOS PÉPTIDOS Y NUEVAS COMBINACIONES DE PÉPTIDOS PARA EL USO DE LA INMUNOTERAPIA CONTRA EL CÁNCER DE PULMÓN, INCLUYENDO EL NSCLC, EL SCLC Y OTROS CÁNCERES (Divisional 2020-0059) |
| MX2020002891A (es) | 2017-09-18 | 2021-01-08 | S & P Ingredient Dev Llc | Sustituto de sal bajo en sodio con cloruro de potasio. |
| CN118888004A (zh) | 2017-10-10 | 2024-11-01 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
| US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
| DE102018108996B4 (de) | 2018-02-09 | 2021-10-21 | Immatics US, Inc. | Verfahren zur Herstellung autologer T-Zellen |
| CN111684062A (zh) | 2018-02-09 | 2020-09-18 | 伊玛提克斯美国公司 | 制造t细胞的方法 |
| DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| JP7480064B2 (ja) * | 2018-02-27 | 2024-05-09 | グリットストーン バイオ インコーポレイテッド | パンアレルモデルによる新生抗原の特定方法 |
| EP3539562A1 (en) * | 2018-03-12 | 2019-09-18 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Immunotherapeutic peptides |
| TW202016131A (zh) | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
| US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
| TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
| TW202028224A (zh) | 2018-09-17 | 2020-08-01 | 德商英麥提克生物技術股份有限公司 | B*44限制肽在抗癌免疫治療的用途和相關方法 |
| TW202024121A (zh) | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
| TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
| KR102215578B1 (ko) * | 2019-03-28 | 2021-02-15 | 한국과학기술연구원 | 인간 백혈구 항원에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| ES2991645T3 (es) | 2019-06-06 | 2024-12-04 | Immatics Biotechnologies Gmbh | Clasificación con contraselección mediante péptidos de secuencia similar |
| CN110305209B (zh) * | 2019-07-09 | 2022-09-13 | 福建医科大学附属第一医院 | 用于治疗恶性肿瘤的多肽及其作为疫苗的用途 |
| US20220281942A1 (en) * | 2019-07-30 | 2022-09-08 | University Health Network | T cell receptors and methods of use thereof |
| EP3827840A1 (en) * | 2019-11-29 | 2021-06-02 | Academisch Ziekenhuis Leiden h.o.d.n. LUMC | Teipp peptide variant and uses thereof |
| DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| US11891427B2 (en) | 2020-09-29 | 2024-02-06 | Immatics Biotechnologies Gmbh | Amidated peptides and their deamidated counterparts displayed by non-HLA-a*02 for use in immunotherapy against different types of cancers |
| DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
| TW202241925A (zh) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | 用於不同類型癌症免疫治療的ｈｌａ展示肽 |
| CN120712104A (zh) * | 2022-10-14 | 2025-09-26 | 广东天科雅生物医药科技有限公司 | 针对神经胶质瘤的肽疫苗及其用途 |
| CN117720620B (zh) * | 2023-12-13 | 2024-07-23 | 无锡市儿童医院 | 小分子多肽和其药物组合物、其制药用途 |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8212000B2 (en) * | 1970-02-11 | 2012-07-03 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US8258260B2 (en) * | 1970-02-11 | 2012-09-04 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US8211999B2 (en) * | 1970-02-11 | 2012-07-03 | Immatics Biotechnologies Gmbh | Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules |
| US4440859A (en) | 1977-05-27 | 1984-04-03 | The Regents Of The University Of California | Method for producing recombinant bacterial plasmids containing the coding sequences of higher organisms |
| GR66050B (el) * | 1977-09-20 | 1981-01-14 | Licinvest Ag | |
| US4704362A (en) | 1977-11-08 | 1987-11-03 | Genentech, Inc. | Recombinant cloning vehicle microbial polypeptide expression |
| IE53176B1 (en) | 1978-12-22 | 1988-08-17 | Biogen Nv | Recombinant dna molecules and their method of production |
| US4530901A (en) | 1980-01-08 | 1985-07-23 | Biogen N.V. | Recombinant DNA molecules and their use in producing human interferon-like polypeptides |
| US4678751A (en) | 1981-09-25 | 1987-07-07 | Genentech, Inc. | Hybrid human leukocyte interferons |
| US4766075A (en) | 1982-07-14 | 1988-08-23 | Genentech, Inc. | Human tissue plasminogen activator |
| US4582800A (en) | 1982-07-12 | 1986-04-15 | Hoffmann-La Roche Inc. | Novel vectors and method for controlling interferon expression |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4677063A (en) | 1985-05-02 | 1987-06-30 | Cetus Corporation | Human tumor necrosis factor |
| US4810648A (en) | 1986-01-08 | 1989-03-07 | Rhone Poulenc Agrochimie | Haloarylnitrile degrading gene, its use, and cells containing the gene |
| US4810781A (en) | 1987-01-15 | 1989-03-07 | The George Washington University | Methods of preparing epitopes of tumor associated antigens |
| JPH07508403A (ja) * | 1992-04-03 | 1995-09-21 | ラ ホヤ キャンサー リサーチ ファウンデーション | デコリンフラグメントおよび細胞調節因子を阻害する方法 |
| CA2142007C (en) * | 1992-08-11 | 2007-10-30 | Robert Glen Urban | Immunomodulatory peptides |
| WO1995011923A1 (en) * | 1993-10-29 | 1995-05-04 | Dana-Farber Cancer Institute, Inc. | A novel tumor marker and novel method of isolating same |
| AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
| NZ290089A (en) | 1994-07-27 | 1999-05-28 | Queensland Inst Med Res | Recombinant polyepitope cytotoxic t lymphocyte (ctl) vaccines |
| UY24367A1 (es) * | 1995-11-23 | 2000-10-31 | Boehringer Ingelheim Int | Vacunas contra tumores y procedimiento para su produccion |
| WO1997026328A1 (en) | 1996-01-17 | 1997-07-24 | Imperial College Innovations Limited | Immunotherapy using cytotoxic t lymphocytes (ctl) |
| US6610821B1 (en) * | 1996-07-12 | 2003-08-26 | Mcgill University | Compounds and methods for modulating endothelial cell adhesion |
| EP0988385A2 (en) * | 1997-01-21 | 2000-03-29 | Human Genome Sciences | Tace-like and matrilysin-like polypeptides |
| US6316213B1 (en) | 1997-03-19 | 2001-11-13 | The Board Of Trustees Of The University Of Arkansas | Methods for the early diagnosis of ovarian, breast and lung cancer |
| US6809175B1 (en) | 1997-10-15 | 2004-10-26 | Prof. Dr. Wolf-Georg Forssmann | Cadherin derived growth factor and its use |
| DE19757250A1 (de) * | 1997-12-22 | 1999-07-01 | Forssmann Wolf Georg Prof Dr | Insulin-like growth factor binding protein und seine Verwendung |
| US6746852B1 (en) * | 1998-05-08 | 2004-06-08 | Osi Pharmaceuticals, Inc. | AGS proteins and nucleic acid molecules and uses thereof |
| DE19936563A1 (de) | 1999-08-04 | 2001-02-08 | Boehringer Ingelheim Int | Tumorassoziiertes Antigen |
| DE19938583A1 (de) | 1999-08-18 | 2001-02-22 | Buehler Ag | Verfahren und Vorrichtung zur Herstellung von kristallisationsfähigem Kunststoffmaterial |
| AU2001233114A1 (en) * | 2000-02-04 | 2001-08-14 | Aeomica, Inc. | Methods and apparatus for predicting, confirming, and displaying functional information derived from genomic sequence |
| AU2001277172A1 (en) * | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-trans protein and related reagents and methods of use thereof |
| AU2001295582A1 (en) | 2000-12-20 | 2002-07-01 | GlaxoSmithKline Biologicals (s.a.) | Tumour-related antigens |
| WO2002078516A2 (en) * | 2001-03-30 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| US6867283B2 (en) | 2001-05-16 | 2005-03-15 | Technion Research & Development Foundation Ltd. | Peptides capable of binding to MHC molecules, cells presenting such peptides, and pharmaceutical compositions comprising such peptides and/or cells |
| US7049413B2 (en) * | 2001-05-18 | 2006-05-23 | Ludwig Institute For Cancer Research | MAGE-A3 peptides presented by HLA class II molecules |
| AU2002322280A1 (en) * | 2001-06-21 | 2003-01-21 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| WO2003016471A2 (en) * | 2001-08-13 | 2003-02-27 | Dana-Farber Cancer Institute, Inc. | Periostin-based diagnostic assays |
| US6906036B2 (en) * | 2001-08-16 | 2005-06-14 | Kimberly-Clark Worldwide, Inc. | Anti-aging and wound healing compounds |
| AU2002335824A1 (en) * | 2001-10-12 | 2003-04-22 | Case Western Reserve University | Neuronal regeneration |
| AU2003215244A1 (en) * | 2002-02-14 | 2003-09-04 | Curagen Corporation | Complexes and methods of using same |
| US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| WO2004014867A2 (en) * | 2002-08-13 | 2004-02-19 | Warner-Lambert Company Llc | Matrix metalloproteinase inhibitors and methods for identification of lead compounds |
| US20070224201A1 (en) * | 2002-10-02 | 2007-09-27 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| JP2006515318A (ja) * | 2002-10-29 | 2006-05-25 | ファルマシア・コーポレーション | 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法 |
| KR20060013425A (ko) * | 2003-05-29 | 2006-02-09 | 밀레니엄 파머슈티컬스 인코퍼레이티드 | 유방암의 확인, 평가, 예방 및 요법에 대한 조성물, 키트및 방법 |
| JP2008500952A (ja) * | 2003-07-15 | 2008-01-17 | ジェノバ・リミテッド | 心臓血管障害で減少する分泌ポリペプチド種 |
| EP1757940A1 (en) | 2005-08-26 | 2007-02-28 | Cézanne S.A.S. | In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC |
| ES2341802T3 (es) * | 2005-09-05 | 2010-06-28 | Immatics Biotechnologies Gmbh | Peptidos asociados a tumores unidos promiscuamente a moleculas del antigeno de leucocito humano (hla) de clase ii. |
| PL1760089T3 (pl) * | 2005-09-05 | 2010-03-31 | Immatics Biotechnologies Gmbh | Peptydy towarzyszące nowotworom, wiążące się z cząsteczkami klasy I i II antygenów ludzkich leukocytów (HLA) i związana z nimi szczepionka przeciwnowotworowa |
| EP1795599A1 (en) * | 2005-12-09 | 2007-06-13 | Schuler, Gerold, Prof. Dr. | Methods for generating antigen-specific effector T cells |
-
2005
- 2005-09-05 ES ES07007914T patent/ES2341802T3/es not_active Expired - Lifetime
- 2005-09-05 PT PT07007915T patent/PT1806359E/pt unknown
- 2005-09-05 SI SI200530167T patent/SI1760088T1/sl unknown
- 2005-09-05 EP EP05019254A patent/EP1760088B1/en not_active Expired - Lifetime
- 2005-09-05 DE DE602005020047T patent/DE602005020047D1/de not_active Expired - Lifetime
- 2005-09-05 DK DK07007915.7T patent/DK1806359T3/da active
- 2005-09-05 ES ES07007915T patent/ES2341295T3/es not_active Expired - Lifetime
- 2005-09-05 ES ES05019254T patent/ES2302546T3/es not_active Expired - Lifetime
- 2005-09-05 PL PL07007915T patent/PL1806359T3/pl unknown
- 2005-09-05 SI SI200530994T patent/SI1806359T1/sl unknown
- 2005-09-05 AT AT07007914T patent/ATE461214T1/de active
- 2005-09-05 DK DK05019254T patent/DK1760088T3/da active
- 2005-09-05 DE DE602005020046T patent/DE602005020046D1/de not_active Expired - Lifetime
- 2005-09-05 EP EP07007914A patent/EP1806358B1/en not_active Expired - Lifetime
- 2005-09-05 PT PT07007914T patent/PT1806358E/pt unknown
- 2005-09-05 PL PL05019254T patent/PL1760088T3/pl unknown
- 2005-09-05 SI SI200531005T patent/SI1806358T1/sl unknown
- 2005-09-05 PL PL07007914T patent/PL1806358T3/pl unknown
- 2005-09-05 AT AT05019254T patent/ATE388164T1/de active
- 2005-09-05 AT AT07007915T patent/ATE461215T1/de active
- 2005-09-05 EP EP07007915A patent/EP1806359B1/en not_active Expired - Lifetime
- 2005-09-05 DE DE602005005196T patent/DE602005005196T2/de not_active Expired - Lifetime
- 2005-09-05 PT PT05019254T patent/PT1760088E/pt unknown
- 2005-09-05 DK DK07007914.0T patent/DK1806358T3/da active
-
2006
- 2006-09-05 AT AT06791838T patent/ATE451388T1/de active
- 2006-09-05 PL PL06791838T patent/PL1922335T3/pl unknown
- 2006-09-05 ES ES09011319T patent/ES2373907T3/es active Active
- 2006-09-05 NZ NZ588813A patent/NZ588813A/en not_active IP Right Cessation
- 2006-09-05 CA CA2929252A patent/CA2929252A1/en not_active Abandoned
- 2006-09-05 SI SI200630566T patent/SI1922335T1/sl unknown
- 2006-09-05 DK DK06791838.3T patent/DK1922335T3/da active
- 2006-09-05 KR KR1020137002917A patent/KR101386790B1/ko not_active Expired - Fee Related
- 2006-09-05 ES ES06791838T patent/ES2337399T3/es active Active
- 2006-09-05 AU AU2006289290A patent/AU2006289290B2/en not_active Ceased
- 2006-09-05 BR BRPI0615462-0A patent/BRPI0615462A2/pt not_active Application Discontinuation
- 2006-09-05 PT PT06791838T patent/PT1922335E/pt unknown
- 2006-09-05 EP EP09011317A patent/EP2138509A1/en not_active Withdrawn
- 2006-09-05 JP JP2008528438A patent/JP5627180B2/ja not_active Expired - Fee Related
- 2006-09-05 KR KR1020137002915A patent/KR101386827B1/ko not_active Expired - Fee Related
- 2006-09-05 HR HR20100128T patent/HRP20100128T1/hr unknown
- 2006-09-05 UA UAA200803825A patent/UA98295C2/ru unknown
- 2006-09-05 EA EA200800677A patent/EA013876B1/ru not_active IP Right Cessation
- 2006-09-05 PT PT09011319T patent/PT2135878E/pt unknown
- 2006-09-05 CN CN201510571930.7A patent/CN105440119A/zh active Pending
- 2006-09-05 PL PL09011319T patent/PL2135878T3/pl unknown
- 2006-09-05 KR KR1020087008073A patent/KR101386355B1/ko not_active Expired - Fee Related
- 2006-09-05 SI SI200631206T patent/SI2135878T1/sl unknown
- 2006-09-05 CN CN2006800383657A patent/CN101287754B/zh not_active Expired - Fee Related
- 2006-09-05 AT AT09011319T patent/ATE532795T1/de active
- 2006-09-05 CA CA2621389A patent/CA2621389C/en not_active Expired - Fee Related
- 2006-09-05 WO PCT/EP2006/008642 patent/WO2007028574A2/en not_active Ceased
- 2006-09-05 CN CN201210560635.8A patent/CN103059104B/zh not_active Expired - Fee Related
- 2006-09-05 DK DK09011319.2T patent/DK2135878T3/da active
- 2006-09-05 EP EP09011319A patent/EP2135878B1/en active Active
- 2006-09-05 US US11/912,670 patent/US10196432B2/en active Active
- 2006-09-05 DE DE602006011030T patent/DE602006011030D1/de active Active
- 2006-09-05 NZ NZ566104A patent/NZ566104A/en not_active IP Right Cessation
- 2006-09-05 EP EP06791838A patent/EP1922335B1/en active Active
-
2007
- 2007-11-19 US US11/942,394 patent/US20080206216A1/en not_active Abandoned
- 2007-11-19 US US11/942,620 patent/US7833970B2/en active Active
- 2007-11-19 US US11/942,573 patent/US7807642B2/en active Active
- 2007-11-19 US US11/942,598 patent/US7833969B2/en active Active
-
2008
- 2008-04-04 NO NO20081683A patent/NO340870B1/no not_active IP Right Cessation
- 2008-05-28 CY CY20081100554T patent/CY1107973T1/el unknown
-
2010
- 2010-02-19 CY CY20101100169T patent/CY1109849T1/el unknown
- 2010-05-27 CY CY20101100469T patent/CY1110051T1/el unknown
- 2010-06-11 CY CY20101100520T patent/CY1110187T1/el unknown
- 2010-10-26 AU AU2010236029A patent/AU2010236029B2/en not_active Ceased
-
2011
- 2011-12-09 CY CY20111101223T patent/CY1112186T1/el unknown
- 2011-12-30 HR HR20110981T patent/HRP20110981T1/hr unknown
-
2015
- 2015-11-05 US US14/933,077 patent/US10618945B2/en active Active
-
2016
- 2016-07-26 HK HK16108913.9A patent/HK1220709A1/zh unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1107973T1 (el) | Σχετιζομενα με ογκους πεπτιδια, που συνδεονται ετεροκλητως με μορια κλασεως ιι αντιγονου ανθρωπινων λευκοκυτταρων | |
| ATE440107T1 (de) | Tumorassoziierte peptide, die hla klasse i oder ii-moleküle binden, und anti-tumor impfstoffe | |
| PL1642905T3 (pl) | Epitopy immunogenicznych komórek pomocniczych T z antygenów guzów ludzkich oraz sposoby immunoterapeutyczne wykorzystujące te epitopy |